Literature DB >> 22788765

Circumventing melanoma chemoresistance by targeting DNA repair.

S Mocellin1, L Bertazza, C Benna, P Pilati.   

Abstract

Available evidence demonstrates that the DNA repair machinery is involved in melanoma resistance to chemotherapeutics. Furhtermore, preclinical findings suggest that interfering with DNA repair could increase chemosensitivity of melanoma cells. However, the clinical implementation of these principles is still in its infancy and no such strategy is currently proven to be effective in patients with advanced melanoma. Since the molecular mechanisms governing the relationship between chemoresistance and DNA repair are not fully elucidated, more basic and translational research is needed to understand the reasons for the failures and to identify novel targets. In this review we summarize the experimental and clinical findings that are fostering the research in this promising field of oncology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22788765     DOI: 10.2174/092986712802002509

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  2 in total

1.  Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.

Authors:  Vito Michele Garrisi; Sabino Strippoli; Simona De Summa; Rosamaria Pinto; Antonella Perrone; Gabriella Guida; Amalia Azzariti; Michele Guida; Stefania Tommasi; Tommasi Stefania
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

2.  The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Authors:  Michele Guida; Stefania Tommasi; Sabino Strippoli; Maria Iole Natalicchio; Simona De Summa; Rosamaria Pinto; Antonio Cramarossa; Anna Albano; Salvatore Pisconti; Michele Aieta; Ruggiero Ridolfi; Amalia Azzariti; Gabriella Guida; Vito Lorusso; Giusepe Colucci
Journal:  BMC Cancer       Date:  2018-05-10       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.